Results 241 to 250 of about 177,994 (348)

Impact of organic pollutants on phenotype and gene expression in human breast cancer cells

Journal of Applied Toxicology, Volume 46, Issue 5, Page 1487-1505, May 2026.
ABSTRACT Human exposure to industrial chemical compounds is widespread and, although often beneficial, prolonged contact may contribute to disease development, including cancer. While many studies have shown organic pollutants (OP) are cytotoxic, few have explored how long‐term exposure alters cell phenotype.
Camila Confortin, Heloisa Amancio, Jessica Zablocki da Luz, Aliciane de Almeida Roque, Tugstênio Lima de Souza, José Eduardo Vargas, Ciro Alberto de Oliveira Ribeiro, Francisco Filipak Neto   +7 more
wiley   +1 more source

MMTV Virus Detection, Survival Analysis, and Prognostic Relevance of Six Tumor Genes in Patients With Breast Cancer. [PDF]

Int J Breast Cancer
Alamri S, Awadalla M, Henawi RA, Al-Hazzaa G, Alkhunaizy Z, Alzorgi S, Alqahtani N, Abdel Halim AS, Ali MAM, Almansour MI, Alosaimi B.   +10 more
europepmc   +1 more source

Prophylactic salpingo-oophorectomy among BRCA1 or BRCA2 mutation carriers. Review of 264 files seen at the Centre Alexis Vautrin from 1970 to 2009

, 2011
Nicole Dzomo
openalex   +1 more source

Limitations of Subgroup Safety Analyses for Drug–Drug Interaction Evaluation: Insights from the Talazoparib P‐gp Inhibitor Case

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Impact of concomitant medications (conmeds) on the safety of the investigational agent is often evaluated using subgroup analyses for safety events in patients who received the conmed versus those who did not. Here, we highlight the potential biases and inconclusive results that can arise from such analyses, using talazoparib and P ...
Diane Wang, Charvi Nanavati, Derek Z. Yang, Liza DeAnnuntis, Mohamed Elmeliegy   +4 more
wiley   +1 more source

Case report: a rare BRCA1 de novo variant in a female with breast cancer. [PDF]

Hered Cancer Clin Pract
Dencker C, Strehlow V, Aktas B, Lemke J, Hentschel J.   +4 more
europepmc   +1 more source

Carrier screening in the reproductive setting—Are there medical implications for the heterozygote?—A guide for clinicians

Pregnancy, Volume 2, Issue 3, May 2026.
Abstract Carrier screening for genetic conditions performed preconception or during pregnancy allows identification of fetal risk for inherited autosomal recessive and X‐linked conditions. The goal is to identify at‐risk patients/couples and offer them reproductive options such as preimplantation genetic diagnosis, prenatal testing, or targeted newborn
Emily B. Rosenfeld, Nicole Kasatkin, Bi Liu Yu, Milen Velinov, Justin S. Brandt, Elena Ashkinadze   +5 more
wiley   +1 more source

Risk of Breast and Ovarian Cancer After Prophylactic Mastectomy and Salpingo-Oophorectomy in BRCA1/2 Germline Variant Carriers: A Retrospective Cohort Study From a Single German Center. [PDF]

Cancer Med
Mendes S, Yahiaoui-Doktor M, Fallenberg EM, Kiechle M, Grill S.   +4 more
europepmc   +1 more source

Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation

The Prostate, Volume 86, Issue 6, Page 727-731, May 2026.
ABSTRACT Background Methyl Methanesulfonate‐Sensitivity Protein 22‐Like (MMS22L) plays a key role in homology‐directed DNA repair, and experimental models have shown that its loss confers sensitivity to Poly (ADP‐ribose) polymerase inhibitors (PARPi).
Mayuko Kanayama, Violet A. Daniels, Marta Gielzak, Alex Brame, Misop Han, Li Jia, Jianfeng Xu, Tamara L. Lotan, Mario A. Eisenberger, Catherine H. Marshall, Patrick C. Walsh, William B. Isaacs, Jun Luo   +12 more
wiley   +1 more source

Psychologically informed reminder messages for promoting BRCA1/2 carrier screening: evidence from a large-scale population-based study. [PDF]

Eur J Public Health
Mushkat T, Greenberg R, Isakov O, Hayek S, Raskas H, Ben-Shachar S, Berliner-Senderey A.   +6 more
europepmc   +1 more source

At the Right Time: Temporal Precision in Personalised Medicine

Sociology of Health &Illness, Volume 48, Issue 4, May 2026.
ABSTRACT Personalised medicine was initially heralded as delivering ‘the right drug to the right patient at the right time’. Although molecular precision has dominated recent developments, the temporal dimension has remained underexplored. This paper examines how temporal precision is emerging as a defining feature of next‐generation precision medicine,
Dominik Hofmann, Elena Esposito
wiley   +1 more source